Prilenia filed a European Marketing Authorization Application (MAA) with the EMA. What's next for the United States?

To learn more about this news and Pridopidine, please read our press release here: Prilenia’s Pridopidine for Huntington’s Disease Accepted for European Marketing Authorisation Review | Prilenia Therapeutics B.V.